AZD 5904 is an irreversible inhibitor of myeloperoxidase (MPO; IC50 = 0.2 ?M in a cell-free assay).1 It enhances decreases in the mitochondrial membrane potential in, and the viability of, MOLM-14 acute myeloid leukemia (AML) cells when used in combination with cytarabine .2 AZD 5904 (75 ?mol/kg) prevents high-fat diet-induced increases in microvascular blood flow and microvascular blood volume in rats.3
1.Tidén, A.-K., Sj?gren, T., Svensson, M., et al.2-Thioxanthines are mechanism-based inactivators of myeloperoxidase that block oxidative stress during inflammationJ. Biol. Chem.286(43)37578-37589(2011) 2.Hosseini, M., Rezvani, H.R., Aroua, N., et al.Targeting myeloperoxidase disrupts mitochondrial redox balance and overcomes cytarabine resistance in human acute myeloid leukemiaCancer Res.79(20)5191-5203(2019) 3.Chai, W., Aylor, K., Liu, Z., et al.Inhibiting myeloperoxidase prevents onset and reverses established high-fat diet-induced microvascular insulin resistanceAm. J. Physiol. Endocrinol. Metab.317(6)E1063-E1069(2019)